Drug Resistance Updates

(The TQCC of Drug Resistance Updates is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance254
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment159
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors151
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update148
Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets136
Anticancer drug resistance: An update and perspective109
The role of alternative splicing in cancer: From oncogenesis to drug resistance108
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming107
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy106
Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification99
Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance98
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies97
Therapeutic strategies to overcome taxane resistance in cancer93
Towards the overcoming of anticancer drug resistance mediated by p53 mutations92
Novel nanomedicines to overcome cancer multidrug resistance89
Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs87
Hypoxia as a driver of resistance to immunotherapy84
A review on antimicrobial botanicals, phytochemicals and natural resistance modifying agents from Apocynaceae family: Possible therapeutic approaches against multidrug resistance in pathogenic microor76
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses75
Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance74
Nanomedicine to target multidrug resistant tumors68
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function56
Repurposing old drugs to fight multidrug resistant cancers56
Emerging roles of F-box proteins in cancer drug resistance54
Antimicrobial peptides for combating drug-resistant bacterial infections46
New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma45
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer44
Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance42
COVID-19 update: The race to therapeutic development42
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer40
Thirty years of VRE in Germany – “expect the unexpected”: The view from the National Reference Centre for Staphylococci and Enterococci37
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects37
Impact of cancer metabolism on therapy resistance – Clinical implications37
The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology37
Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition37
Overcoming cancer chemotherapy resistance by the induction of ferroptosis35
Cross-resistance and drug sequence in prostate cancer35
Metallothionein isoforms as double agents – Their roles in carcinogenesis, cancer progression and chemoresistance35
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine34
Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance31
The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies31
Molecular Modeling Strategies of Cancer Multidrug Resistance30
In vitro biomimetic models for glioblastoma-a promising tool for drug response studies29
Long non-coding RNA mediated drug resistance in breast cancer28
Selenium and tellurium in the development of novel small molecules and nanoparticles as cancer multidrug resistance reversal agents27
The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells26
The role of endolysosomal trafficking in anticancer drug resistance23
Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma23